Enveric Biosciences Stock Today
| ENVB Stock | USD 0.31 0.02 6.06% |
Performance0 of 100
| Odds Of DistressOver 85
|
Enveric Biosciences is trading at 0.31 as of the 23rd of December 2024, a 6.06 percent decrease since the beginning of the trading day. The stock's open price was 0.33. Enveric Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 23rd of November 2024 and ending today, the 23rd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of June 2015 | Category Healthcare | Classification Health Care |
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Enveric Biosciences, Inc. is headquartered in Naples, Florida. Enveric Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 9.94 M outstanding shares of which 115.51 K shares are currently shorted by private and institutional investors with about 0.31 trading days to cover. More on Enveric Biosciences
Moving together with Enveric Stock
Moving against Enveric Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Enveric Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEnveric Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enveric Biosciences' financial leverage. It provides some insight into what part of Enveric Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Enveric Biosciences (ENVB) is traded on NASDAQ Exchange in USA. It is located in 4851 Tamiami Trail N, Naples, FL, United States, 34103 and employs 7 people. Enveric Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.23 M. Enveric Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.94 M outstanding shares of which 115.51 K shares are currently shorted by private and institutional investors with about 0.31 trading days to cover.
Enveric Biosciences currently holds about 18.01 M in cash with (14.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Enveric Biosciences Probability Of Bankruptcy
Ownership AllocationEnveric Biosciences shows 6.92 percent of its outstanding shares held by insiders and 7.05 percent owned by other corporate entities.
Check Enveric Ownership Details
Enveric Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Group One Trading, Lp | 2024-09-30 | 273 | |
| Bank Of America Corp | 2024-09-30 | 173 | |
| Nelson, Van Denburg & Campbell Wealth Management Group, Llc | 2024-09-30 | 50.0 | |
| Wells Fargo & Co | 2024-09-30 | 16.0 | |
| Susquehanna International Group, Llp | 2024-06-30 | 0.0 | |
| Fmr Inc | 2024-09-30 | 0.0 | |
| Org Partners Llc | 2024-09-30 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | |
| Mather Group, Inc. | 2024-09-30 | 0.0 | |
| Advisorshares Investments, Llc | 2024-09-30 | 367 K | |
| Geode Capital Management, Llc | 2024-09-30 | 217.9 K |
Enveric Biosciences Historical Income Statement
Enveric Stock Against Markets
Enveric Biosciences Corporate Management
| Joseph Tucker | CEO Director | Profile | |
| Ibrahim MD | Chief Officer | Profile | |
| MBA IV | Interim Officer | Profile | |
| Peter Facchini | Chief Officer | Profile | |
| Avani Kanubaddi | Pres COO | Profile | |
| Kevin CPA | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 37.678 | Quarterly Revenue Growth (0.07) | Return On Assets (0.81) | Return On Equity (2.06) |
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.